DEBRA和Dermaliq伙伴为皮肤紊乱制定新的治疗办法 DEBRA and Dermaliq partner to develop new treatments for the skin disorder Epidermolysis Bullosa.

DEBRA 研究和Dermaliq治疗技术已形成伙伴关系,为流行性透析布洛萨(EB)开发新的治疗方法,布洛萨是一种罕见的遗传疾病,造成脆弱的皮肤和水泡。 DEBRA Research and Dermaliq Therapeutics have formed a partnership to develop new treatments for Epidermolysis Bullosa (EB), a rare genetic disorder causing fragile skin and blisters. 合作的重点是利用Dermaliq的Hyli技术,改善伤口愈合、缓解痒痒和预防性治疗,这种技术提供不触摸的药物供应。 The collaboration will focus on improving wound healing, itch relief, and preventive therapies using Dermaliq's hyliQ® technology, which offers touchless drug delivery. 这旨在改善EB患者的医疗结果和生活质量. This aims to enhance medical outcomes and quality of life for EB patients.